Retreatment with lenalidomide is an effective option in heavily
pretreated refractory multiple myeloma patients

J 2018

Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients

ŠTORK, Martin, Sabina ŠEVČÍKOVÁ, Zdeněk ADAM, Marta KREJČÍ, Viera SANDECKÁ et. al.

Základní údaje

Originální název

Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients

Autoři

ŠTORK, Martin (203 Česká republika), Sabina ŠEVČÍKOVÁ (203 Česká republika, domácí), Zdeněk ADAM (203 Česká republika), Marta KREJČÍ (203 Česká republika), Viera SANDECKÁ (703 Slovensko), Zdeněk KRÁL (203 Česká republika), Lucie BROŽOVÁ (203 Česká republika, domácí), Roberta VELICHOVÁ (703 Slovensko, domácí) a Luděk POUR (203 Česká republika)

Vydání

Neoplasma, Bratislava, Slovenská akademie vied, 2018, 0028-2685

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Slovensko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.771

Kód RIV

RIV/00216224:14110/18:00106916

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.4149/neo_2018_170519N363

UT WoS

000440172400012

Klíčová slova anglicky

multiple myeloma; lenalidomide; retreatment

Štítky

14110518, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 2. 2019 19:22, Soňa Böhmová

Anotace

V originále

The combination of lenalidomide and dexamethasone is the current gold standard for treatment of relapsed multiple myeloma. This study analyzes the efficiency of repeated lenalidomide treatment in patients with relapsed and refractory multiple myeloma. A total of 41 patients were prospectively evaluated at the University Hospital Brno. Lenalidomide was administered at standard dosing and in combination with corticosteroids and/or chemotherapy. The maximum cumulative dose of lenalidomide was limited to 4,200 mg because of Czech health insurance rules. Before the second lenalidomide treatment, all patients were refractory to the last treatment; previously, 95% of patients had bortezomib treatment, 48% had autologous transplantation and the median number of prior therapy lines was three. A partial 14.2% or better response was achieved with the second lenalidomide treatment. The median progression-free survival was 4.8 months, and median overall survival was 11.9 months. Unfortunately, predicting risk factors in lenalidomide retreatment proved unsuccessful. Although our treatment results were significantly affected by limited Czech health care system coverage for lenalidomide, we established that its repeated treatment is an effective therapeutic alternative for heavily pretreated patients with relapsed and refractory multiple myeloma.

Návaznosti

MUNI/A/1106/2016, interní kód MU

Název: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit IV (Akronym: VýDiTeHeMA IV)

Investor: Masarykova univerzita, Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit IV, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

NV15-29508A, projekt VaV

Název: Cirkulující nukleové kyseliny jako markery progrese mnohočetného myelomu

Citovat

ŠTORK, Martin, Sabina ŠEVČÍKOVÁ, Zdeněk ADAM, Marta KREJČÍ, Viera SANDECKÁ, Zdeněk KRÁL, Lucie BROŽOVÁ, Roberta VELICHOVÁ a Luděk POUR. Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients. Neoplasma. Bratislava: Slovenská akademie vied, 2018, roč. 65, č. 4, s. 585-591. ISSN 0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo_2018_170519N363.

@article{1404546,
   author = {Štork, Martin and Ševčíková, Sabina and Adam, Zdeněk and Krejčí, Marta and Sandecká, Viera and Král, Zdeněk and Brožová, Lucie and Velichová, Roberta and Pour, Luděk},
   article_location = {Bratislava},
   article_number = {4},
   doi = {http://dx.doi.org/10.4149/neo_2018_170519N363},
   keywords = {multiple myeloma; lenalidomide; retreatment},
   language = {eng},
   issn = {0028-2685},
   journal = {Neoplasma},
   title = {Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients},
   volume = {65},
   year = {2018}
}

TY  - JOUR
ID  - 1404546
AU  - Štork, Martin - Ševčíková, Sabina - Adam, Zdeněk - Krejčí, Marta - Sandecká, Viera - Král, Zdeněk - Brožová, Lucie - Velichová, Roberta - Pour, Luděk
PY  - 2018
TI  - Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients
JF  - Neoplasma
VL  - 65
IS  - 4
SP  - 585-591
EP  - 585-591
PB  - Slovenská akademie vied
SN  - 00282685
KW  - multiple myeloma
KW  - lenalidomide
KW  - retreatment
N2  - The combination of lenalidomide and dexamethasone is the current gold standard for treatment of relapsed multiple myeloma. This study analyzes the efficiency of repeated lenalidomide treatment in patients with relapsed and refractory multiple myeloma. A total of 41 patients were prospectively evaluated at the University Hospital Brno. Lenalidomide was administered at standard dosing and in combination with corticosteroids and/or chemotherapy. The maximum cumulative dose of lenalidomide was limited to 4,200 mg because of Czech health insurance rules. Before the second lenalidomide treatment, all patients were refractory to the last treatment; previously, 95% of patients had bortezomib treatment, 48% had autologous transplantation and the median number of prior therapy lines was three. A partial 14.2% or better response was achieved with the second lenalidomide treatment. The median progression-free survival was 4.8 months, and median overall survival was 11.9 months. Unfortunately, predicting risk factors in lenalidomide retreatment proved unsuccessful. Although our treatment results were significantly affected by limited Czech health care system coverage for lenalidomide, we established that its repeated treatment is an effective therapeutic alternative for heavily pretreated patients with relapsed and refractory multiple myeloma.
ER  -

ŠTORK, Martin, Sabina ŠEVČÍKOVÁ, Zdeněk ADAM, Marta KREJČÍ, Viera SANDECKÁ, Zdeněk KRÁL, Lucie BROŽOVÁ, Roberta VELICHOVÁ a Luděk POUR. Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients. \textit{Neoplasma}. Bratislava: Slovenská akademie vied, 2018, roč.~65, č.~4, s.~585-591. ISSN~0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo\_{}2018\_{}170519N363.

Podrobný výpis o publikaci